Recent Updates
Recently added Catalysts
PDEX Positive Sentiment

Pro-Dex, Inc. Announces Fiscal 2026 Fourth Quarter and Full-Year Results

Key Takeaway: Pro-Dex, Inc. reported strong financial results for its fiscal 2026 fourth quarter and full year, with a 17% increase in net sales and a 103% rise in gross profit compared to the previous year. The company's acquisition of Advanced Precision Machining contributed positively to revenue growth. However, operating expenses also increased significantly, which could pose challenges moving forward.
Price reaction · baseline $60.7 (2026-09-03T15:53:00.000Z) · hit during market hours · clean, no other PDEX news in the window
day 0 close · peak
+1.7%

Market Sentiment Analysis

POSITIVE FACTORS

  • Net sales increased by 17% in Q4 2026 compared to Q4 2025.
  • Gross profit for Q4 2026 rose by 103%, indicating strong financial performance.
  • Successful acquisition of Advanced Precision Machining (APM) bolstered revenue.

CONCERNS & RISKS

  • Operating expenses increased by 29% for the fiscal year, raising concerns about cost management.
  • A significant allowance for uncollectible receivables may indicate potential financial risks.

Full Press Release Details

IRVINE, CA / ACCESS Newswire / September 3, 2026 / PRO-DEX, INC. (NasdaqCM:PDEX) today announced financial results for its fiscal 2026 fourth quarter and full-year ended June 30, 2026.
Net sales for the three months ended June 30, 2026 increased $2.9 million, or 17%, to $20.4 million from $17.5 million for the three months ended June 30, 2025, due primarily to increased revenue from our largest customer's next generation orthopedic handpiece. Gross profit for the three months ended June 30, 2026 increased $3.6 million, or 103%, to $7.1 million from $3.5 million for the three months ended June 30, 2025 similarly attributable to increased revenue from our largest customer's next generation handpiece. During much of the fourth quarter of fiscal 2025, we were shipping our largest customer its legacy handpiece, until the customer released its product hold on the next generation handpiece late in that quarter, at which point we resumed production and shipment of its next generation handpiece late in the same quarter. Our gross margin increased from 20% for the three months ended June 30, 2025, to 35% for the three months ended June 30, 2026, due to favorable product mix, better absorption of our indirect manufacturing costs and favorable margins derived from our subsidiary, Advanced Precision Machining, LLC ("APM"), which we acquired in the third quarter of fiscal 2026.
Operating expenses (which include selling, general and administrative, and research and development expenses) for the quarter ended June 30, 2026, increased $1.4 million to $3.6 million, compared to $2.2 million for the prior fiscal year's corresponding quarter. Selling, general and administrative expenses increased by $1.3 million, and research and development expenses increased by $111,000 for the quarter ended June 30, 2026, compared to the corresponding quarter in fiscal 2025. The increases relate primarily to a $349,000 allowance for uncollectible receivables, $436,000 of APM's separate administrative expenses, $250,000 in consulting payments paid to the founder of APM to assist with our manufacturing operations, as well as increased personnel and related expenses to support our continued growth.
Our operating income for the quarter ended June 30, 2026, increased $2.2 million, or 163%, to $3.5 million compared to $1.3 million for the prior fiscal year's corresponding quarter. The increase reflects our increased gross profit partially offset by higher operating expenses, as described above.
Net income for the quarter ended June 30, 2026, increased by $1.7 million to $2.9 million, or $0.87 per diluted share, compared to $1.2 million, or $0.36 per diluted share, in the corresponding quarter in 2025.
Net sales for the fiscal year ended June 30, 2026 increased $10.9 million, or 16%, to $77.5 million from $66.6 million for the fiscal year ended June 30, 2025, due primarily to a of $15.3 million increase in revenue from our largest customer, related primarily to its next generation orthopedic handpiece, offset by a $6.0 million reduction in repair revenue, primarily from our largest customer. Additionally, our NRE revenue increased $952,000 in the fiscal year ended June 30, 2026 compared to the prior fiscal year and APM added $718,000 in revenue since our acquisition of APM on February 9, 2026.
Gross profit for the fiscal year ended June 30, 2026, increased $4.8 million, or 25%, to $24.3 million compared to $19.5 million for fiscal 2025. Our gross margin increased from 29% in fiscal 2025 to 31% in fiscal 2026, due to overall favorable product mix.
Operating expenses (which include selling, general and administrative, and research and development expenses) for the fiscal year ended June 30, 2026, increased $2.5 million or 29% to $11.3 million from $8.8 million in the prior fiscal year. The increase relates primarily to an increase of $1.2 million in personnel costs included in general and administrative expenses to support our continued growth, which amount includes $582,000 of company-wide bonus accruals and non-cash equity compensation expense, as well as $500,000 in non-recurring consulting fees paid to APM's founder, $669,000 of APM's separate operating expenses, and the $349,000 allowance for uncollectible receivables referenced above. The decrease in research and development expenses in fiscal 2026 is primarily related to a decrease in legal expenses related to intellectual property matters.
Our operating income for the year ended June 30, 2026, increased $2.3 million, or 22%, to $13.0 million compared to $10.7 million for the prior fiscal year's corresponding quarter. The increase reflects our increased sales and gross profit, as described above.
Net income for the fiscal year ended June 30, 2026, was $13.7 million, or $4.12 per diluted share, compared to $9.0 million, or $2.67 per diluted share, for fiscal 2025. Our net income for the fiscal years ended June 30, 2026 and 2025 contains gains on our marketable equity investments of $5.7 million and $2.1 million, respectively. All of our investments are recorded at estimated fair value, and the valuation can be highly volatile.
"We are very pleased with our fiscal 2026 performance including completing the acquisition of APM and increasing sales by 16%," said the Company's President and Chief Executive Officer Richard L. ("Rick") Van Kirk. "I continue to extend my gratitude to the Pro-Dex team for their continued teamwork and focus on execution," Mr. Van Kirk concluded.
Pro-Dex, Inc. specializes in the design, development, and manufacture of autoclavable, battery-powered, and electric multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and maxocranial facial markets. We have patented adaptive torque-limiting software and proprietary sealing solutions that appeal to our customers, primarily medical device distributors. Additionally, we provide engineering, quality, and regulatory consulting services to our customers. Our APM subsidiary manufactures parts and assemblies for the aerospace and defense industries in addition to providing several machined components to support Pro-Dex's customers. Pro-Dex, Inc. also sells rotary air motors to a wide range of industries; however, these air motors comprise a de minimis portion of our business. Pro-Dex's products are found in hospitals and medical engineering labs around the world. For more information, visit the Company's websites at www.pro-dex.com and www.advanced-precision.com .
Statements herein concerning the Company's plans, growth and strategies may include "forward-looking statements" within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance as well as management's expectations, beliefs, plans, estimates, or projections relating to the future, are forward-looking statements within the meaning of these laws. The Company's actual results may differ materially from those suggested as a result of various factors. Interested parties should refer to the disclosure concerning the operational and business risks of the Company set forth in the Company's filings with the Securities and Exchange Commission, including its Annual Report of Form 10-K. The Company undertakes no obligation to update any forward-looking statement, except as required by law.
PRO-DEX, INC. AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS (In thousands, except share data)
PRO-DEX, INC. AND SUBSIDIARIES CONSOLIDATED INCOME STATEMENTS (In thousands, except per share data)
PRO-DEX, INC. AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF CASH FLOWS (In thousands)

Frequently Asked Questions

What were Pro-Dex's net sales for Q4 2026?

Pro-Dex's net sales for Q4 2026 were $20.4 million, a 17% increase from Q4 2025.

How much did Pro-Dex's gross profit increase in Q4 2026?

Gross profit for Q4 2026 increased by 103%, reaching $7.1 million.

What contributed to Pro-Dex's revenue growth?

Revenue growth was primarily driven by sales from the next generation orthopedic handpiece.

What was the impact of the APM acquisition on Pro-Dex?

The acquisition of APM added significant revenue and improved the overall product mix.

Did Pro-Dex experience an increase in operating expenses?

Yes, operating expenses increased by 29% for the fiscal year, raising concerns.

Last updated: Sep 3, 2026